Vascular Protection with Dipeptidyl Peptidase‐IV inhibitors in Diabetes: Experimental and Clinical Therapeutics

By  

PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, Vol. 35, Iss. 3, 2015-03 ,pp. : 277-297

John Wiley & Sons Inc

Access to resources Recommend Favorite

Expression of CD26/dipeptidyl‐peptidase IV in benign and malignant pigment‐cell lesions of the skin

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 138, Iss. 4, 1998-04 ,pp. : 615-621

John Wiley & Sons Inc

Access to resources Recommend Favorite

Increased Expression of Dipeptidyl Peptidase IV in Human Mesothelial Cells by Malignant Ascites from Ovarian Carcinoma Patients

By  

Oncology, Vol. 63, Iss. 2, 2002-09 ,pp. : 158-165

Karger

Access to resources Recommend Favorite

Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers

By He Y.-L.   Zhang Y.   Serra D.   Wang Y.   Ligueros-Saylan M.   Dole W.P.  

Current Medical Research and Opinion, Vol. 27, Iss. 7, 2011-07 ,pp. : 1453-1463

Informa Healthcare

Access to resources Recommend Favorite

Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects

By He Yan-Ling   Sabo Ron   Riviere Gilles-Jacques   Sunkara Gangadhar   Leon Selene   Ligueros-Saylan Monica   Rosenberg Mitchell   Dole William P.   Howard Dan  

Current Medical Research and Opinion, Vol. 23, Iss. 5, 2007-05 ,pp. : 1131-1138

Informa Healthcare

Access to resources Recommend Favorite